Vascularity, measured by CD34 staining, grouped tumours into a vascular group of tumours (ccRCC, 12.6% positivity; oncocytoma, 10.4%; and chRCC, 7.1%) and non-vascular tumours (pRCC, 2.8%). This evidence concerns the gene CD34 and nonpapillary renal cell carcinoma.